Sydmarken 11
SOeborg
Copenhagen 2860
Denmark
45 88 77 36 00
https://www.zealandpharma.com
Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 253
Name | Titel | Zahlen | Ausgeübt | Geburtsjahr |
---|---|---|---|---|
Mr. Adam Sinding Steensberg M.D. | President & CEO | 1,59M | N/A | 1974 |
Ms. Henriette Wennicke | EVP & CFO | 650,68k | N/A | 1983 |
Mr. Ivan Mourits Moller | Executive VP & COO | N/A | N/A | 1972 |
Dr. David M. Kendall M.D. | Chief Medical Officer and Head of R&D | N/A | N/A | 1961 |
Mr. Mads Kronborg | Head of Investor Relations & Communication | N/A | N/A | N/A |
Mr. Ravinder Singh Chahil | EVP & General Counsel | N/A | N/A | 1968 |
Ms. Christina Sonnenborg Bredal | Executive VP & Chief People Officer | N/A | N/A | 1985 |
Dr. Jens Damsgaard Mikkelsen M.D. | Head of Molecular Pharmacology | N/A | N/A | N/A |
Dr. Danilo Verge | Head of Global Medical Affairs | N/A | N/A | N/A |
Lykke Romer | VP & Head of Finance and Accounting | N/A | N/A | N/A |
Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon. Its pipeline includes Dasiglucagon that is in Phase III clinical trials for treating congenital hyperinsulinism. The company is also developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. The company was incorporated in 1997 and is based in Søborg, Denmark.
Zealand Pharma A/Ss ISS Governance QualityScore, Stand 1. Mai 2024, lautet 3. Die grundlegenden Scores sind Audit: 5, Vorstand: 1, Shareholderrechte: 1, Kompensation: 8.